成功血管内再灌注后动脉内阿替普酶治疗急性卒中:PEARL随机临床试验
PEARL多中心随机试验纳入324例前循环大血管闭塞卒中患者,血栓切除成功再灌注后随机接受动脉内阿替普酶(0.225 mg/kg,最大20 mg)或标准治疗。症状性颅内出血和90天全因死亡率两组差异无统计学意义。
要点
- 血栓切除成功再灌注后动脉内阿替普酶可提高90天极佳功能结局比例。
- 症状性颅内出血36小时内两组差异无统计学意义(4.3% vs 5.0%)。
- 90天全因死亡率和36小时内任何颅内出血动脉内阿替普酶组数值更高但无统计学意义。
核心结论
- 前循环大血管闭塞卒中患者血栓切除成功再灌注后,动脉内阿替普酶较标准治疗提高90天极佳功能结局可能性。
- 动脉内阿替普酶组全因死亡率和任何颅内出血发生率数值更高,但差异无统计学意义。
研究设计与样本
- 纳入症状发作24小时内前循环大血管闭塞卒中、血栓切除后成功再灌注(eTICI≥2b50)患者,允许指南推荐静脉溶栓。
- 共324例随机:动脉内阿替普酶组164例,标准治疗组160例;中位年龄68岁(IQR 58-75),女性99例(30.6%)。
- 干预为动脉内阿替普酶0.225 mg/kg(最大剂量20 mg)对比标准治疗;每组1例失访。
关键数值与推荐
- 主要结局为90天mRS评分0或1的比例(mRS范围0无症症状至6死亡,0或1为极佳结局)。
- 成功再灌注定义为eTICI评分≥2b50。
- 安全性结局包括随机后36小时内症状性颅内出血、90天内全因死亡、36小时内任何颅内出血。
- 试验注册号ClinicalTrials.gov NCT05856851。
临床怎么用
- 对于前循环大血管闭塞卒中血栓切除成功再灌注患者,可考虑动脉内阿替普酶0.225 mg/kg(最大20 mg)以改善90天功能结局。
- 应用时需权衡全因死亡率和任何颅内出血数值升高但无统计学意义的信号。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Functional outcomes in patients with acute ischemic stroke due to large-vessel occlusion who undergo thrombectomy remain suboptimal, and the benefits of intra-arterial alteplase after thrombectomy remain uncertain. OBJECTIVE: To investigate whether treatment with intra-arterial alteplase after successful endovascular reperfusion improves functional outcomes among patients with acute, anterior-circulation, large-vessel occlusion stroke. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized clinical trial recruited patients with anterior-circulation, large-vessel occlusion stroke within 24 hours of symptom onset who achieved successful reperfusion (expanded Thrombolysis in Cerebral Infarction scale score of ≥2b50) after thrombectomy. Guideline-based intravenous thrombolysis was allowed. Patients were randomized between August 1, 2023, and October 16, 2024, and the trial was conducted at 28 hospitals in China. Final follow-up occurred on January 7, 2025. INTERVENTIONS: Intra-arterial alteplase treatment (n = 164) with 0.225 mg/kg (maximum dose of 20 mg) vs standard treatment (n = 160). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days (score range, 0 [no symptoms] to 6 [death]; a score of 0 or 1 indicates an excellent outcome). The safety outcomes included symptomatic intracranial hemorrhage within 36 hours of randomization, all-cause mortality within 90 days, and any intracranial hemorrhage within 36 hours. RESULTS: Of the 324 patients randomized (median age, 68 years [IQR, 58-75 years]; 99 were female [30.6%]), 1 patient in each group was lost to follow-up. The proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days was 44.8% (73/163) in the intra-arterial alteplase group vs 30.2% (48/159) in the standard treatment group (adjusted risk ratio [RR], 1.45 [95% CI, 1.08-1.96]; P = .01). The proportion of patients with symptomatic intracranial hemorrhage within 36 hours was 4.3% (7/164) in the intra-arterial alteplase group vs 5.0% (8/160) in the standard treatment group (adjusted RR, 0.85 [95% CI, 0.43-1.69]; P = .67). The proportion of patients with all-cause mortality within 90 days was 17.1% (28/164) in the intra-arterial alteplase group vs 11.3% (18/160) in the standard treatment group (adjusted hazard ratio, 1.60 [95% CI, 0.88-2.89]; P = .12). The proportion of patients with any intracranial hemorrhage within 36 hours was 32.9% (54/164) in the intra-arterial alteplase group vs 26.9% (43/160) in the standard treatment group (adjusted RR, 1.22 [95% CI, 0.92-1.63]; P = .17). CONCLUSIONS AND RELEVANCE: Among patients with acute, anterior-circulation, large-vessel occlusion stroke who achieved successful endovascular reperfusion by mechanical thrombectomy, intra-arterial alteplase resulted in a higher likelihood of excellent outcomes at 90 days. The incidence of all-cause mortality and any intracranial hemorrhage was higher in patients who received intra-arterial alteplase, although these differences were not statistically significant. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05856851.
引用
- Yang X, He X, Xu Y, et al. Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial. JAMA. 2025. PMID: 42262770. doi:10.1001/jama.2025.16876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。